Current status of thiopurine analogues in the treatment in Crohn's disease

P. Lakatos, Lajos S. Kiss

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In the last decades, with the development of biological therapy, the treatment paradigms in patients with Crohn's disease have continuously evolved. Several studies focusing on the optimal use of both traditional immunosuppressants and biological therapy have been published, investigating conventional, accelerated step-up and top-down approaches. In addition, much emphasis has been placed in recent years on the determination of important predictive factors that could enable early patient stratifcation, which would lead to a tailored management strategy. In this review, the authors try to highlight new evidence on the optimal timing, benefits, and risks of immunosuppressants alone, or in combination, in patients with Crohn's disease.

Original languageEnglish
Pages (from-to)4372-4381
Number of pages10
JournalWorld Journal of Gastroenterology
Volume17
Issue number39
DOIs
Publication statusPublished - Oct 21 2011

Fingerprint

Crohn Disease
Biological Therapy
Immunosuppressive Agents
Therapeutics

Keywords

  • Azathioprine
  • Biologicals
  • Crohn's disease
  • Immunosuppressives
  • Thiopurine methyltransferase

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Current status of thiopurine analogues in the treatment in Crohn's disease. / Lakatos, P.; Kiss, Lajos S.

In: World Journal of Gastroenterology, Vol. 17, No. 39, 21.10.2011, p. 4372-4381.

Research output: Contribution to journalArticle

@article{61d568360168405ab36fcdf7f54073bd,
title = "Current status of thiopurine analogues in the treatment in Crohn's disease",
abstract = "In the last decades, with the development of biological therapy, the treatment paradigms in patients with Crohn's disease have continuously evolved. Several studies focusing on the optimal use of both traditional immunosuppressants and biological therapy have been published, investigating conventional, accelerated step-up and top-down approaches. In addition, much emphasis has been placed in recent years on the determination of important predictive factors that could enable early patient stratifcation, which would lead to a tailored management strategy. In this review, the authors try to highlight new evidence on the optimal timing, benefits, and risks of immunosuppressants alone, or in combination, in patients with Crohn's disease.",
keywords = "Azathioprine, Biologicals, Crohn's disease, Immunosuppressives, Thiopurine methyltransferase",
author = "P. Lakatos and Kiss, {Lajos S.}",
year = "2011",
month = "10",
day = "21",
doi = "10.3748/wjg.v17.i39.4372",
language = "English",
volume = "17",
pages = "4372--4381",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "39",

}

TY - JOUR

T1 - Current status of thiopurine analogues in the treatment in Crohn's disease

AU - Lakatos, P.

AU - Kiss, Lajos S.

PY - 2011/10/21

Y1 - 2011/10/21

N2 - In the last decades, with the development of biological therapy, the treatment paradigms in patients with Crohn's disease have continuously evolved. Several studies focusing on the optimal use of both traditional immunosuppressants and biological therapy have been published, investigating conventional, accelerated step-up and top-down approaches. In addition, much emphasis has been placed in recent years on the determination of important predictive factors that could enable early patient stratifcation, which would lead to a tailored management strategy. In this review, the authors try to highlight new evidence on the optimal timing, benefits, and risks of immunosuppressants alone, or in combination, in patients with Crohn's disease.

AB - In the last decades, with the development of biological therapy, the treatment paradigms in patients with Crohn's disease have continuously evolved. Several studies focusing on the optimal use of both traditional immunosuppressants and biological therapy have been published, investigating conventional, accelerated step-up and top-down approaches. In addition, much emphasis has been placed in recent years on the determination of important predictive factors that could enable early patient stratifcation, which would lead to a tailored management strategy. In this review, the authors try to highlight new evidence on the optimal timing, benefits, and risks of immunosuppressants alone, or in combination, in patients with Crohn's disease.

KW - Azathioprine

KW - Biologicals

KW - Crohn's disease

KW - Immunosuppressives

KW - Thiopurine methyltransferase

UR - http://www.scopus.com/inward/record.url?scp=81755188303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81755188303&partnerID=8YFLogxK

U2 - 10.3748/wjg.v17.i39.4372

DO - 10.3748/wjg.v17.i39.4372

M3 - Article

C2 - 22110262

AN - SCOPUS:81755188303

VL - 17

SP - 4372

EP - 4381

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 39

ER -